Sandoz Sets Out Solid Growth In First Standalone Results
Biosimilars Help To Drive 9M Increases; Firm Also Issues CHF750m In Inaugural Bonds
Reporting its first results as a standalone company, Sandoz has delivered double-digit growth in biosimilars for the first nine months of 2023, helping to lift the overall business as generics also enjoyed a more modest increase.
